PERS&O (PERsistent Sitagliptin treatment & Outcomes): observational retrospective study on cardiovascular risk evolution in patients with type 2 diabetes on persistent sitagliptin treatment.

Giulia BuonaiutoValentina De MoriAlessandra BrausAnnalisa BaliniDenise BerziRita CarpinteriFranco ForloniGiancarla MeregalliGian Luca Ronco Antonio Carlo Bossi

Published in: BMJ open diabetes research & care (2016)

These 'real-world' data obtained applying UKPDS RE may reflect patients' and clinicians' interest in realizing individual CV risk, and its evolution. Sitagliptin-persistent treatment for a medium-long period obtained an improvement on metabolic control, as well as a reduction on CV risk.

Keyphrases

end stage renal disease
palliative care
peritoneal dialysis
prognostic factors
machine learning
electronic health record
patient reported outcomes
big data